Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Scandion Oncology (OMX: SCOL)

Last close As at 21/11/2024

1.36

▲ −0.03 (−2.16%)

Market capitalisation

SEK56m

Latest Insights

View More

Healthcare | Update

Scandion Oncology — An active quarter with AML plans in the mix

Flash note

Scandion Oncology — PANTAX Phase I trial meets primary endpoint

Healthcare | Flash note

Scandion Oncology — Expanding SCO-101 into AML

Healthcare | Update

Scandion Oncology — A defining year ahead for SCO-101
Visit Website

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (11.6) (39.0) (84.4)
Relative (9.5) (41.4) (86.2)
52 week high/low SEK8.7/SEK1.4

Financials

Edison Investment Research is terminating coverage on Scandion Oncology (SCOL). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec Revenue (DKKm) EBITDA (DKKm) PBT (DKKm) EPS (ore) P/E (x) P/CF (x)
2021A 0.8 (54.8) (57.2) (161.0) N/A N/A
2022A 2.1 (79.3) (82.2) (187.0) N/A N/A
2023E 0.6 (65.3) (65.3) (147.0) N/A N/A
2024E 0.6 (69.0) (69.4) (157.0) N/A N/A

Flash note

Healthcare

Scandion Oncology — PANTAX dosing schedule expanded

Flash note

Healthcare

Scandion Oncology — Outcome of rights issue

Initiation

Healthcare

Scandion Oncology — Chemotherapy overcoming drug resistance

edison tv

Healthcare

Scandion Oncology: Edison Open House Healthcare 2022

QuickView

Healthcare

Scandion Oncology — Drug-resistant cancer solutions